California Dilantin SJS Lawsuits: Fight for Compensation
TL;DR: SJS/TEN are rare but severe reactions reported with Dilantin (phenytoin). FDA labeling warns about these risks and notes genetic factors such as HLA-B1502 in some patients of Asian ancestry (see FDA labels). In California, potential claims include failure to warn and other product liability theories, but suits against generic makers face strong federal preemption. California also recognizes certain claims against brand-name manufacturers even if a generic was taken. Deadlines can be short—talk to a California attorney promptly.
Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) linked to Dilantin (phenytoin) can cause catastrophic injuries. This guide outlines potential California claims, what evidence helps, who may be liable, and practical next steps.
What Is Dilantin and How Is It Linked to SJS/TEN?
Dilantin (generic name: phenytoin) is an anti-seizure medication. In rare cases, serious skin reactions such as SJS and TEN have been reported in connection with phenytoin exposure. These reactions can begin with flu-like symptoms and progress to painful rash, blistering, skin detachment, eye involvement, and multi-organ complications. Early medical treatment is critical.
FDA-approved labeling warns of serious dermatologic reactions including SJS/TEN and provides guidance on risk factors and monitoring (Dilantin label; phenytoin sodium label). The labeling also notes increased risk associated with the HLA-B1502 allele in some individuals of Asian ancestry.
Warning Information and Known Risks
The FDA labeling for phenytoin includes warnings about SJS/TEN, potential genetic risk factors (e.g., HLA-B*1502), significant drug–drug interactions, and dosing considerations (FDA label). Discuss your risk profile and early warning signs with your prescribing clinician, and seek immediate medical care if symptoms appear.
Potential Legal Theories in California
Depending on the facts, California plaintiffs may pursue claims such as:
- Failure to warn about known or knowable risks;
- Design defect or negligent design;
- Manufacturing defect;
- Negligence;
- Breach of warranties; and
- Fraud or misrepresentation.
Claims may be asserted against brand-name manufacturers, generic manufacturers (subject to federal preemption), distributors, and in some cases healthcare entities if prescribing or monitoring fell below the standard of care.
Important constraints and California specifics:
- Federal preemption for generic drugs: Many failure-to-warn and design-defect claims against generic manufacturers are preempted because generic makers generally cannot unilaterally change the drug’s labeling or design (PLIVA, Inc. v. Mensing; Mutual Pharm. Co. v. Bartlett).
- Innovator liability in California: California courts recognize that, in some circumstances, a brand-name manufacturer may be liable for negligent labeling or misrepresentations even if the plaintiff ingested a generic equivalent (T.H. v. Novartis; Conte v. Wyeth).
The viability of each theory depends on the evidence and the defendant’s role in the drug’s design, labeling, and distribution.
What You Must Prove
In pharmaceutical product cases, plaintiffs typically must show: (1) the product was defective or warnings were inadequate when it left the defendant’s control; (2) the defect or inadequate warning was a substantial factor in causing SJS/TEN; and (3) legally cognizable damages. Causation in SJS/TEN cases often requires expert testimony connecting exposure, timing of symptoms, a differential diagnosis ruling out other causes, and support from medical literature.
Evidence That Helps Your Case
- Prescription records, pharmacy labels, and medication guides
- Hospital and dermatology records, biopsy/pathology reports, and photographs
- Adverse-event timelines (first dose, symptom onset, ER visit, ICU/burn unit care)
- Correspondence with prescribers and insurers
- Employer records for lost wages
- Product labeling versions in effect at the time of use
- Expert opinions in pharmacology, dermatology, ophthalmology, and life-care planning
Practical Tips
- Keep a medication diary noting start/stop dates and any dose changes.
- Ask your clinician to document suspected drug causality in the chart.
- Avoid discarding pill bottles; they show lot numbers and NDCs.
- Centralize bills and receipts to track economic losses.
Checklist for Your Records
- Photos of rash/eye involvement with dates
- Complete hospital records and biopsy/pathology reports
- Pharmacy printouts and Medication Guides
- List of all medications and start/stop dates
- Work absence and wage documentation
Damages You May Seek
Recoverable damages in California may include medical expenses, future care and rehabilitation, lost wages and diminished earning capacity, pain and suffering, scarring and disfigurement, and loss of consortium (where applicable). In appropriate cases, punitive damages may be available if the evidence meets California’s standard (Civ. Code § 3294).
Deadlines to File in California
Time limits vary by claim type and circumstances. As general guidance (with many exceptions):
- Personal injury/product liability: Often two years from the injury or its discovery (CCP § 335.1).
- Medical malpractice (against healthcare providers): Generally one year after discovery, and no more than three years after injury, with exceptions (CCP § 340.5).
- Claims involving public entities: Often require a government claim within six months (Gov. Code § 911.2).
Because timing rules are complex and exceptions may apply, speak with a California attorney promptly to protect your rights.
What To Do If You Suspect SJS/TEN from Dilantin
- Seek immediate medical care; SJS/TEN is a medical emergency.
- Preserve the medication, packaging, and pharmacy information.
- Document symptoms and take photos of skin and eye involvement.
- Request complete medical records and discharge summaries.
- Avoid stopping prescription medication without medical advice.
- Contact a California product liability attorney to evaluate your options.
How Our Firm Helps
We investigate your medication history, secure medical and pharmacy records, consult leading experts, evaluate labeling and regulatory history, identify all potentially responsible parties, and pursue claims in the appropriate forum. We handle negotiations with insurers and defendants and, when necessary, take cases to trial.
Frequently Asked Questions
- Can I sue over generic phenytoin? Federal preemption may limit certain claims against generic manufacturers (Mensing; Bartlett). Other avenues may exist depending on the facts, including potential claims against brand-name innovators in California (T.H. v. Novartis; Conte v. Wyeth).
- What if I stopped Dilantin years ago? Some claims may still be viable depending on discovery rules and other factors, but deadlines may run quickly. Talk to counsel promptly.
- Do I need an expert? SJS/TEN pharmaceutical cases almost always require expert testimony to establish causation and damages.
Next Steps
If you or a loved one suffered SJS/TEN after taking Dilantin (phenytoin), contact our California team for a free, confidential consultation. We can review your timeline, preserve critical evidence, and advise on the best strategy to pursue compensation. Get in touch now.
References
- FDA Dilantin (phenytoin) label
- FDA phenytoin sodium label
- PLIVA, Inc. v. Mensing, 564 U.S. 604 (2011)
- Mutual Pharm. Co. v. Bartlett, 570 U.S. 472 (2013)
- T.H. v. Novartis Pharm. Corp., 4 Cal.5th 145 (2017)
- Conte v. Wyeth, Inc., 168 Cal.App.4th 89 (2008)
- Cal. Code Civ. Proc. § 335.1
- Cal. Code Civ. Proc. § 340.5
- Cal. Gov’t Code § 911.2
- Cal. Civ. Code § 3294
Legal and Medical Disclaimer
This blog provides general information and is not legal or medical advice. Reading it does not create an attorney–client relationship. Legal deadlines and outcomes vary by facts and jurisdiction; consult a licensed California attorney about your specific situation.